Antonella Tosco

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7405924/publications.pdf

Version: 2024-02-01

45 papers	1,227 citations	394421 19 h-index	361022 35 g-index
47 all docs	47 docs citations	47 times ranked	1475 citing authors

#	Article	IF	Citations
1	Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. Autophagy, 2014, 10, 2053-2074.	9.1	135
2	Clinical, HLA, and Small Bowel Immunohistochemical Features of Children with Positive Serum Antiendomysium Antibodies and Architecturally Normal Small Intestinal Mucosa. American Journal of Gastroenterology, 2005, 100, 2294-2298.	0.4	120
3	Natural History of Potential Celiac Disease in Children. Clinical Gastroenterology and Hepatology, 2011, 9, 320-325.	4.4	105
4	Potential Celiac Children: 9-Year Follow-Up on a Gluten-Containing Diet. American Journal of Gastroenterology, 2014, 109, 913-921.	0.4	89
5	A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR. Cell Death and Differentiation, 2016, 23, 1380-1393.	11.2	82
6	Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation. Cell Death and Disease, 2018, 8, e2544-e2544.	6.3	67
7	Immunoglobulin A Antiâ€tissue Transglutaminase Antibody Deposits in the Small Intestinal Mucosa of Children With No Villous Atrophy. Journal of Pediatric Gastroenterology and Nutrition, 2008, 47, 293-298.	1.8	59
8	Potential Celiac Patients: A Model of Celiac Disease Pathogenesis. PLoS ONE, 2011, 6, e21281.	2.5	49
9	A pathogenic role for cystic fibrosis transmembrane conductance regulator in celiac disease. EMBO Journal, 2019, 38, .	7.8	43
10	Intestinal deposits of anti-tissue transglutaminase IgA in childhood celiac disease. Digestive and Liver Disease, 2011, 43, 604-608.	0.9	39
11	High density of intraepithelial Î³Î´ lymphocytes and deposits of immunoglobulin (Ig)M anti-tissue transglutaminase antibodies in the jejunum of coeliac patients with IgA deficiency. Clinical and Experimental Immunology, 2010, 160, 199-206.	2.6	35
12	Serum and Intestinal Celiac Diseaseâ€“associated Antibodies in Children With Celiac Disease Younger Than 2 Years of Age. Journal of Pediatric Gastroenterology and Nutrition, 2010, 50, 43-48.	1.8	33
13	A survey of the prevalence, management and outcome of infants with an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis (CRMS/CFSPID) in six Italian centres. Journal of Cystic Fibrosis, 2021, 20, 828-834.	0.7	32
14	Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis. Molecular and Cellular Pediatrics, 2016, 3, 13.	1.8	31
15	Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2015, 14, 203-210.	0.7	29
16	Intestinal anti-tissue transglutaminase antibodies in potential coeliac disease. Clinical and Experimental Immunology, 2012, 171, 69-75.	2.6	28
17	Prediction of acute pancreatitis risk based on PIP score in children with cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 579-584.	0.7	25
18	Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: A randomized multicenter study. PLoS ONE, 2019, 14, e0213497.	2.5	22

#	Article	IF	Citations
19	Lung structure and function similarities between primary ciliary dyskinesia and mild cystic fibrosis: a pilot study. Italian Journal of Pediatrics, 2017, 43, 34.	2.6	21
20	Autophagy suppresses the pathogenic immune response to dietary antigens in cystic fibrosis. Cell Death and Disease, 2019, 10, 258.	6.3	17
21	CRMS/CFSPID Subjects Carrying D1152H CFTR Variant: Can the Second Variant Be a Predictor of Disease Development?. Diagnostics, 2020, 10, 1080.	2.6	17
22	Cystic Fibrosis-Screening Positive Inconclusive Diagnosis: Newborn Screening and Long-Term Follow-Up Permits to Early Identify Patients with CFTR-Related Disorders. Diagnostics, 2020, 10, 570.	2.6	16
23	Glucose Tolerance Stages in Cystic Fibrosis Are Identified by a Unique Pattern of Defects of Beta-Cell Function. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1793-1802.	3.6	16
24	Streptococcus pneumoniae oropharyngeal colonization in children and adolescents with cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 366-371.	0.7	14
25	Intraâ€individual biological variation in sweat chloride concentrations in CF, CFTR dysfunction, and healthy pediatric subjects. Pediatric Pulmonology, 2018, 53, 728-734.	2.0	13
26	Cystic fibrosis transmembrane conductance regulator (CFTR) and autophagy: hereditary defects in cystic fibrosis versus gluten-mediated inhibition in celiac disease. Oncotarget, 2019, 10, 4492-4500.	1.8	13
27	Intestinal titres of anti-tissue transglutaminase 2 antibodies correlate positively with mucosal damage degree and inversely with gluten-free diet duration in coeliac disease. Clinical and Experimental Immunology, 2014, 177, 611-617.	2.6	12
28	Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype. Journal of Cystic Fibrosis, 2022, 21, 850-855.	0.7	12
29	Outcomes of early repeat sweat testing in infants with cystic fibrosis transmembrane conductance regulatorâ€related metabolic syndrome/CF screenâ€positive, inconclusive diagnosis. Pediatric Pulmonology, 2021, 56, 3785-3791.	2.0	11
30	Discriminant Score for Celiac Disease Based on Immunohistochemical Analysis of Duodenal Biopsies. Journal of Pediatric Gastroenterology and Nutrition, 2015, 60, 621-625.	1.8	10
31	Genistein antagonizes gliadin-induced CFTR malfunction in models of celiac disease. Aging, 2019, 11, 2003-2019.	3.1	8
32	Interaction between Streptococcus pneumoniae and Staphylococcus aureus in paediatric patients suffering from an underlying chronic disease. International Journal of Immunopathology and Pharmacology, 2015, 28, 497-507.	2.1	7
33	Repurposing therapies for the personalised treatment of cystic fibrosis. Expert Opinion on Orphan Drugs, 2018, 6, 361-373.	0.8	6
34	Mutation-specific therapies and drug repositioning in cystic fibrosis. Minerva Pediatrica, 2019, 71, 287-296.	2.7	5
35	May the new suggested lower borderline limit of sweat chloride impact the diagnostic process for cystic fibrosis?. Journal of Pediatrics, 2018, 194, 261-262.	1.8	2
36	Succinate links mitochondria to deadly bacteria in cystic fibrosis. Annals of Translational Medicine, 2019, 7, S263-S263.	1.7	2

#	Article	IF	Citations
37	Personalization of therapies in rare diseases: a translational approach for the treatment of cystic fibrosis. Minerva Pediatrica, 2019, 71, 362-370.	2.7	1
38	Non-invasive tools for detection of liver disease in children and adolescents with cystic fibrosis. Translational Pediatrics, 2021, 10, 0-0.	1.2	1
39	Serum and intestinal IgA anti-tissue transglutaminase antibodies in coeliac children under 2 years of age. Digestive and Liver Disease, 2007, 39, A81.	0.9	0
40	Kinetics of anti-TG2 antibodies release into organ culture supernatants in celiac disease. Digestive and Liver Disease, 2014, 46, e112.	0.9	0
41	Cystic Fibrosis: New Insights into Therapeutic Approaches. Current Respiratory Medicine Reviews, 2020, 15, 174-186.	0.2	0
42	Longâ€term benefits of nusinersen in a child affected by cystic fibrosis and spinal muscular atrophy type 1. Pediatric Pulmonology, 2021, 56, 1806-1808.	2.0	0
43	Diabetes outbreak during COVID19 lock-down in a prediabetic patient with cystic fibrosis long treated with glargine. Italian Journal of Pediatrics, 2021, 47, 121.	2.6	0
44	Renal involvement in cystic fibrosis: is it a contraindication to transplant?. Minerva Pediatrics, 2019, , .	0.4	0
45	A complicated association between two different genetic rare disorders: Cystic Fibrosis and Spinal Muscular Atrophy. Minerva Pediatrics, 2021, , .	0.4	0